This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

PHA-739358 for Treatment of Hormone Refractory Prostate Cancer

This study has been completed.
Information provided by (Responsible Party):
Nerviano Medical Sciences Identifier:
First received: October 2, 2008
Last updated: May 13, 2014
Last verified: May 2014
To assess the antitumor activity of PHA-739358 administered as IV infusion according to two different dose schedules in metastatic HRPC patients progressing on standard, docetaxel-based 1st-line chemotherapy for HRPC based on PSA response, and to select the best dose schedule for further investigation.

Condition Intervention Phase
Metastatic Hormone Refractory Prostate Cancer Drug: PHA-739358 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Study of PHA-739358 in Patients With Metastatic Hormone Refractory Prostate Cancer

Resource links provided by NLM:

Further study details as provided by Nerviano Medical Sciences:

Primary Outcome Measures:
  • PSA response rate defined according to the recommendations from the Prostate-Specific Antigen Working Group [ Time Frame: within the first three months of treatment ]

Secondary Outcome Measures:
  • Objective Response Rate, Progression Free Survival, additional PSA based endpoints, clinical benefit [ Time Frame: all cycles ]
  • Overall safety profile [ Time Frame: all cycles ]

Enrollment: 118
Study Start Date: September 2007
Study Completion Date: April 2011
Primary Completion Date: March 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: A Drug: PHA-739358
6-hr IV infusion weekly for 3 consecutive weeks in a 4-week cycle
Experimental: B Drug: PHA-739358
24-hr IV infusion every 2 weeks in a 4-week cycle


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Metastatic hormone refractory prostate cancer progressing after docetaxel based therapy
  • Adequate bone marrow, liver and kidney function

Exclusion Criteria:

  • More than one prior chemotherapy line
  • Uncontrolled hypertension
  • Brain or leptomeningeal disease
  • Myocardial infarction, severe/unstable angina, symptomatic congestive heart failure, cerebrovascular accident in the previous 6 months
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00766324

Nerviano Medical Sciences. Clinical Research Dept.
Nerviano, Milano, Italy, 20014
Sponsors and Collaborators
Nerviano Medical Sciences
  More Information

Responsible Party: Nerviano Medical Sciences Identifier: NCT00766324     History of Changes
Other Study ID Numbers: AURA-6202-007
Study First Received: October 2, 2008
Last Updated: May 13, 2014

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs processed this record on September 19, 2017